|
Week
|
0
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
|---|
| |
Baseline
|
Treatment period (4 to 8 session)
| | | |
Follow-up
|
|---|
|
Sign informed consent
|
√
| | | | | | | | |
|
TNSS
|
√
|
√
|
√
|
√
|
√
| | | | |
|
TNNSS
|
√
|
√
|
√
|
√
|
√
| | | | |
|
Physical sign
|
√
|
√
|
√
|
√
|
√
| | | | |
|
RQLQ score
|
√
|
√
|
√
|
√
|
√
| | | | |
|
IgE level
|
√
| | | |
√
| | | | |
|
Eosinophil count
|
√
| | | |
√
| | | | |
|
Number of days with moderate-severe PER in the last month
|
√
| | | | | | | |
√
|
|
Allergen test
|
√
| | | | | | | | |
|
Randomization
|
√
| | | | | | | | |
|
Onset time
| |
√
|
√
|
√
|
√
| | | | |
|
Duration of effectiveness in every session
| |
√
|
√
|
√
|
√
| | | | |
|
Waiting time
| |
√
|
√
|
√
|
√
| | | | |
|
Adverse event
| |
√
|
√
|
√
|
√
| | | | |
- TNSS, Total nasal symptom score; TNNSS, Total non-nasal symptom score; RQLQ, Rhinoconjunctivitis Quality of Life Questionnaire.
